Novartis AG (NVS): Price and Financial Metrics
Novartis AG (NVS)
Today's Latest Price: $87.05 USD
Updated Sep 28 7:00pm
Add NVS to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 239 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
NVS Stock Summary
- NVS has a market capitalization of $197,304,889,390 -- more than approximately 99.3% of US stocks.
- The volatility of Novartis Ag's share price is greater than that of only 1.02% US stocks with at least 200 days of trading history.
- Novartis Ag's shareholder yield -- a measure of how much capital is returned to stockholders via dividends and buybacks -- is 8.58%, greater than the shareholder yield of 78.87% of stocks in our set.
- Stocks that are quantitatively similar to NVS, based on their financial statements, market capitalization, and price volatility, are PFE, MRK, SAP, NVO, and NFLX.
- Visit NVS's SEC page to see the company's official filings. To visit the company's web site, go to www.novartis.com.
NVS Stock Price Chart Technical Analysis Charts
NVS Price/Volume Stats
| Current price | $87.05 | 52-week high | $99.84 |
| Prev. close | $87.11 | 52-week low | $69.18 |
| Day low | $86.99 | Volume | 1,011,240 |
| Day high | $87.74 | Avg. volume | 2,150,359 |
| 50-day MA | $86.39 | Dividend yield | 2.31% |
| 200-day MA | $87.82 | Market Cap | 199.23B |
Novartis AG (NVS) Company Bio
Novartis AG offers patented prescription medicines in various therapeutic areas, such as oncology, cardio-metabolic, immunology and dermatology, retina, respiratory, neuroscience, and established medicines. The company was founded in 1895 and is based in Basel, Switzerland.
NVS Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $87.05 | $58.92 | -32% |
We started the process of determining a valid price forecast for Novartis Ag with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Novartis Ag ranked in the 35th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Novartis Ag, consider:
- The compound growth rate in the free cash flow of Novartis Ag over the past 5.01 years is 0.03%; that's higher than only 23.37% of free cash flow generating stocks in the Healthcare sector.
- NVS's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 32.16% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -34% |
| 1% | -33% |
| 2% | -32% |
| 3% | -32% |
| 4% | -31% |
| 5% | -30% |
EDAP, BDX, IQV, ITGR, and GILD can be thought of as valuation peers to NVS, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...